RespireRx Pharmaceuticals Inc. Announces a Department of Defense Award to Fund a Phase 2 Clinical Study to Determine the Safety and Efficacy of CX1739, its Lead AMPAkine, to Improve Bladder Function in Patients with Spinal Cord Injury
RespireRx Pharmaceuticals Inc. Announces Positive Results from Phase 2B PACE Study Conducted by the University of Illinois Dronabinol Reduces Symptoms of Obstructive Sleep Apnea
RespireRx Pharmaceuticals Inc. Announces Data for CX1739 Clinical Study in Opioid Induced Respiratory Depression
SAGA Metals Announces Additional Assay Results from Drilling at Trapper North, Confirming High-Grade Mineralization at Radar Critical Minerals Project in Labrador
Providence Gold Mines Inc. Announces Final Approval of Reviewable Transaction and The La Dama de Oro Gold Property NI43 101 Report
